Meiwu Technology Co Ltd current report, Q2 FY2022

Meiwu Technology Company Limited — Form 6-K Summary

Business context and reporting period

Meiwu Technology Company Limited filed this Form 6-K for April 2022. On April 28, 2022, the Company entered into a Securities Purchase Agreement with five accredited investors for a private financing transaction.

Financing and key terms

  • Gross proceeds: $5.0 million, or $1.0 million per investor.
  • Debt issued: Five unsecured convertible notes with aggregate original principal of $5.5 million, including a $100,000 original issue discount per note and $4,000 per note for purchaser fees, costs, and transaction expenses.
  • Interest: 10% per annum, compounded daily.
  • Maturity: Outstanding principal and accrued interest are due 18 months after issuance.
  • Conversion: Each note may be converted after the six-month anniversary at the lower of $0.50 per share or 80% of the lowest daily volume-weighted average price during the preceding 20 trading days.
  • Warrants: Each investor receives warrants to purchase 1.6 million ordinary shares, for an aggregate of 8.0 million shares. The warrants are immediately exercisable, have an initial exercise price of $0.60 per share, and expire 24 months after issuance.
  • Prepayment: The Company may prepay all or part of a note at 120% of the outstanding balance being prepaid.
  • Use of proceeds: Working capital and general corporate purposes.

Financial performance and liquidity

The filing does not provide revenue, profitability, cash flow, margin, balance-sheet, existing-debt, or liquidity metrics for the period. The financing is intended to provide working capital and general corporate funding.

Material changes, outlook, and risks

  • The transaction adds $5.5 million of convertible debt principal and related interest obligations while providing $5.0 million of gross cash proceeds.
  • Conversion terms based on a discount to market price may result in issuance of additional ordinary shares at prices below $0.50, creating potentially substantial dilution.
  • Exercise of the warrants could result in issuance of up to 8.0 million additional ordinary shares.
  • The purchasers agreed not to sell more than 15% of weekly trading volume in any calendar week, but future conversions and warrant exercises may still affect trading price and share supply.
  • The Company may incur a significant repayment premium if it prepays the notes, and must repay principal plus accrued interest at maturity if the notes are not converted.
  • The securities are offered under Section 4(a)(2) and/or Regulation D and are not registered under the Securities Act.
  • The filing provides no specific management guidance or broader operating outlook.

Investor verification items

  • Confirm the final issuance date, maturity date, accrued interest, and outstanding balance of each note.
  • Review the filed forms of the Securities Purchase Agreement, notes, and warrants for complete contractual terms, default provisions, and investor remedies.
  • Verify the number of ordinary shares outstanding and the potential dilution from note conversions and the 8.0 million warrant shares.
  • Assess the applicable conversion price using the relevant 20-trading-day volume-weighted average prices.
  • Evaluate whether operating cash flow and available liquidity will be sufficient to service or repay the notes.